CHEK1 and cancer: Thus, inhibiting the ATR-CHK1 pathway has been an attractive strategy to selectively sensitize G1/S checkpoint-deficient cancer cells to therapies that damage DNA, without compromising normal cells with proficient the G1/S checkpoint [38].